GenSci140 / GeneScience - LARVOL DELTA

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=170 | Not yet recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P1 trial • Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

GenSci140: A potential best-in-class biparatopic FRα-targeting ADC with broadened patient coverage in ovarian and other cancers (ESMO 2025) - "While IMGN853/ELAHERE TM , a FRα-targeting ADC, has been approved for platinum-resistant epithelial ovarian cancer (PROC) patients with high FRα expression, only limited activity was observed in the lower FRα-expressing populations...Combination of GenSci140 and Keytruda demonstrated synergistic effects in CDX model...Legal entity responsible for the study Changchun GeneScience Pharmaceutical Co., Ltd. Funding Changchun GeneScience Pharmaceutical Co., Ltd."

Clinical • Endometrial Cancer • Epithelial Ovarian Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • FOLR1

GenSci140, a potential best-in-class FRα-directed biparatopic ADC, for the treatment of platinum-resistant ovarian cancer (AACR 2025) - "GenSci140 demonstrated superior in vivo anti-tumor efficacy compared to ELAHERETM and IMGN151 (competitor's next-generation FRα-directed biparatopic ADC product) across a variety of CDX models including ovarian cancer, NSCLC, and TNBC, irrespective of their FRα expression levels. These data suggest that GenSci140 could be a more effective and safer treatment option than the current standard of care for 2L PROC, potentially addressing the unmet need of patients with varying levels of FRα expression. Therapeutic potential of this molecule is currently further evaluated in IND-enabling studies."

Platinum resistant • Breast Cancer • Endometrial Cancer • Epithelial Ovarian Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • FOLR1